Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006
about
Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices.Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysisAdvancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis.Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents.Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.Comparison of diagnostic accuracy of Doppler USG and contrast-enhanced magnetic resonance angiography and selective renal arteriography in patients with atherosclerotic renal artery stenosis.Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 casesAssociation of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease.Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure.Understanding nephrogenic systemic fibrosis
P2860
Q24602293-04CBBE15-0FFB-4102-9041-AE757723A9DFQ24654124-73CDE83A-9B0C-4538-BA67-1EB0F3CEAF72Q34223200-476980DB-3358-4544-8FA3-CBC46721C717Q35664137-F019DBDA-6E49-46B4-8D43-BC0674C0A0F7Q36129149-2C0E7EF9-4829-4EF7-81DB-CF3F1658D8A2Q36324674-39225D62-E658-4BA8-B900-D855B8E2084DQ36954689-01266281-53F7-41A9-A5D4-3CF9985A80FCQ37145493-3C6F0748-D63D-4240-9B87-E07C3C41A68BQ37219177-92A6D10F-1489-4C33-A77B-7E1AE6B4F3F6Q39587499-17CA5922-25C6-4508-B20E-C3A7075B587FQ40319469-8F52F9C9-80A5-43AD-B39C-776CC8525174Q41545279-B19B7A38-BD83-42DB-82BF-C81B7051F285
P2860
Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Nephrogenic fibrosing dermopat ...... St. Louis, Missouri, 2002-2006
@ast
Nephrogenic fibrosing dermopat ...... St. Louis, Missouri, 2002-2006
@en
Nephrogenic fibrosing dermopat ...... St. Louis, Missouri, 2002-2006
@nl
type
label
Nephrogenic fibrosing dermopat ...... St. Louis, Missouri, 2002-2006
@ast
Nephrogenic fibrosing dermopat ...... St. Louis, Missouri, 2002-2006
@en
Nephrogenic fibrosing dermopat ...... St. Louis, Missouri, 2002-2006
@nl
prefLabel
Nephrogenic fibrosing dermopat ...... St. Louis, Missouri, 2002-2006
@ast
Nephrogenic fibrosing dermopat ...... St. Louis, Missouri, 2002-2006
@en
Nephrogenic fibrosing dermopat ...... St. Louis, Missouri, 2002-2006
@nl
P1476
Nephrogenic fibrosing dermopat ...... St. Louis, Missouri, 2002-2006
@en
P304
P407
P577
2007-02-23T00:00:00Z